3 days popular7 days popular1 month popular3 months popular

EyeTechCare focused ultrasound treatment device gains CE mark extension to treat surgery-naive glaucoma

EyeTechCare SA, which develops and sells non-invasive therapeutic medical devices for ophthalmology, has announced that it has received CE mark extension to new indications for its treatment. The medical procedure will now address all patients living with uncontrolled irrespective of their prior . This innovative and non-invasive therapy reduces intraocular pressure by utilizing proprietary focused ultrasound technology. It benefits from a very good safety profile and offers a predictable, trouble-free patient follow-up.

Clinical trials for the EyeOP1 device commenced in 2010 (Pilot Study, EyeMUST 1 & 2 studies) and have resulted in excellent outcomes in terms of both tolerance and efficacy. These results compelled the investigators to push for a broader application for this treatment. The aim was to include patients with moderate-stage glaucoma who have not yet undergone surgery. As a result, the company launched the EyeMUST 3 clinical investigation. After 12 months of follow-up, the results of this new trial involving 30 patients proved successful in individuals with under hypotensive medical treatment.

“We are very pleased to expand the indications of our device,” said , CEO of EyeTechCare. “This marks an important milestone in the development of our company, especially from a clinical standpoint. From now on, the treatment can be offered to a far greater number of patients. We are convinced that this new therapeutic procedure will soon play a key role in the management of who are often apprehensive about having surgery.”

Source

Source: EyeTechCare